VRXA Director Christoph Samuel Ziegler Buys $33K of Stock
Key Points
- Veraxa Biotech AG director Christoph Samuel Ziegler bought 30,000 shares of the company on October 20, 2026, spending $32,700 at a price of $1.09 per share.
- The transaction was filed with the U.S. Securities and Exchange Commission, lifting Ziegler's total holdings to 37,932 shares.
- The biotechnology company recently traded around $1.08, well below its 52-week high of $27.36.
Since the trade, $VRXA is up 5.0% to date (from the $1.01 close on Oct 20, 2026).
Get Veraxa Biotech AG - Post de-SPAC text alerts
We text you when insiders, Congress, analysts or big funds move on $VRXA.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Veraxa Biotech AG - Post de-SPAC alert may contain errors. Disclosures
Inside Christoph Samuel Ziegler's Veraxa Biotech Trade
Veraxa Biotech AG director Christoph Samuel Ziegler bought 30,000 shares of the company on October 20, 2026. The purchase was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission. The insider acquired the shares at a price of $1.09 each, totaling $32,700. Following the transaction, Ziegler holds 37,932 shares, representing a 378.21% increase in his direct ownership stake.
VRXA
Veraxa Biotech AG - Post de-SPAC
Other Institutional Activity in Veraxa Biotech AG
Picton Mahoney Asset Management grew its holdings by 87,500 shares, ending with 175,000 shares worth about $185,499. HRT Financial LP grew its holdings by 9,437 shares, ending with 18,874 shares worth about $20,006. Susquehanna International Group, LLP grew its holdings by 5,416 shares, ending with 10,833 shares worth about $11,482. Caitong International Asset Management Co., Ltd grew its holdings by 3 shares, ending with 6 shares worth about $6. Wolverine Asset Management, LLC grew its holdings by 874 shares, ending with 1,748 shares worth about $1,852.
Veraxa Biotech AG - Post de-SPAC Stock Up 6.9%
Veraxa Biotech recently traded around $1.08 as of October 21, 2026. That puts the stock up about 9.1% since its 52-week low of $0.99, while it remains down about 96.1% from its 52-week high of $27.36. The shares are also positioned below both their 50-day and 200-day moving averages.
Recent Earnings
Veraxa Biotech reported trailing twelve-month revenue of $23,426 alongside a trailing twelve-month loss per share of $0.57. The company registered a return on equity of -871.4%.
About Veraxa Biotech AG
Veraxa Biotech AG is a Heidelberg, Germany-based biotechnology company operating in the healthcare sector. The firm focuses on developing antibody-based therapeutics, which include antibody-drug conjugates and bispecific antibody formats for cancer treatment. It also provides a proprietary technology platform designed for functional antibody screening and bioconjugation.
Bottom Line
Director Christoph Samuel Ziegler's open-market purchase brings fresh attention to the insider ownership side of the company following recent share price pressure. Market watchers will track upcoming filings and updates from the biotechnology firm to gauge its ongoing operational progress.
Related Filing Alerts
Source: Christoph Samuel Ziegler's Form 4 filing on $VRXA (Oct 20, 2026). Written by software, not financial advice. How we make alerts